Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3318-9709
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees86
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
How were Myovant Sciences' earnings last quarter?
Myovant Sciences Ltd (NYSE:MYOV) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.06. View Myovant Sciences' Earnings History.
When is Myovant Sciences' next earnings date?
What price target have analysts set for MYOV?
8 analysts have issued 1 year target prices for Myovant Sciences' shares. Their forecasts range from $20.00 to $26.00. On average, they anticipate Myovant Sciences' stock price to reach $24.50 in the next year. This suggests a possible upside of 385.1% from the stock's current price. View Analyst Price Targets for Myovant Sciences.
What is the consensus analysts' recommendation for Myovant Sciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.
Has Myovant Sciences been receiving favorable news coverage?
Media coverage about MYOV stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myovant Sciences earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Myovant Sciences.
Are investors shorting Myovant Sciences?
Myovant Sciences saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,300,000 shares, an increase of 25.0% from the August 30th total of 2,640,000 shares. Based on an average daily trading volume, of 332,800 shares, the days-to-cover ratio is presently 9.9 days. Approximately 11.4% of the company's shares are sold short. View Myovant Sciences' Current Options Chain.
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS), Akcea Therapeutics (AKCA), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR) and Insmed (INSM).
What other stocks do shareholders of Myovant Sciences own?
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)
- Mr. Frank L. Karbe, Chief Financial Officer (Age 51)
- Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)
- Ms. Julie Tran MBA, MSHR, Sr. VP of HR
- Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51)
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.
How do I buy shares of Myovant Sciences?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of MYOV stock can currently be purchased for approximately $5.05.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $452.58 million. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.
What is Myovant Sciences' official website?
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-3318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
